A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
Study of DKN-01 in Combination with Tislelizumab & Chemotherapy in Patients with Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer
Sponsor: Leap Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU3670
U.S. Govt. ID: NCT04363801
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: You are being invited to take part in a research study that includes studying DKN-01 combined with another investigational drug called tislelizumab and your physicians choice of a combination of drugs generally used to treat your type of cancer, either capecitabine and oxaliplatin (referred to as CAPOX) OR leucovorin calcium, fluorouracil, and oxaliplatin (referred to as mFOLFOX6) in advanced gastric or gastroesophageal junction (GEJ) cancer. DKN-101 works by targeting the DKK1 protein, which is present in high levels in your type of tumor. The purpose of this study is to find out if combining DKN-01 with tislelizumab and CAPOX (capecitabine + oxaliplatin) or mFOLFOX6 (leucovorin calcium + fluorouracil + oxaliplatin) will be safe and if it will delay the chance of your cancer growing or spreading.
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with advanced gastric or gastroesophageal junction (GEJ) cancer? Yes No
Are you willing to have the study drug administered through a vein in your arm? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162